Royalty Pharma (RPRX, Drugmakers) Stock Valuation & Fair Value
Trading above its usual valuationRoyalty Pharma (RPRX, Drugmakers) trades at a current P/E of 12.7, about 31% above its historical normal valuation, with a forward growth estimate of 11.6% and a PEG of 1.10. Analysts' one-year estimates have been hit 40% of the time. Priced at its historical normal P/E of 9.7 on the same blended earnings, the 2026-11-06 close of $67.30 corresponds to about $51.20 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $67.30 at the Nov 6 close, 6.0% above the 20-day average ($63.48) and 10.7% above the 50-day ($60.82).
- RSI (14) at 72.7.
- 52-week range $37.57 to $67.57: the price is 0.4% below the high and 79.1% above the low.
The Street vs SeerForecast
Wall Street's mean price target for RPRX is $65.38 across 8 analysts, 2.9% below the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: trading above its usual valuation. When the two disagree, start your digging there.
Valuation flags
- Long-term debt is over half its capital (54%)
- Overvalued by 31%
- Overbought (RSI 73)
Verdict history
tickerseer's rating changed 4 times after 2026-07-31 and is back where it started: trading above its usual valuation as of 2026-11-02.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 30 readings
Frequently asked questions
Is Royalty Pharma stock overvalued?
At a current P/E of 12.7 versus its historical normal P/E of 9.7, Royalty Pharma trades about 31% above its typical valuation, with a PEG of 1.10 on 11.6% forward growth. tickerseer currently rates it trading above its usual valuation.
What is Royalty Pharma's fair value and PEG?
Royalty Pharma trades at a current P/E of 12.7 against a historical normal P/E of 9.7, a PEG of 1.10, and a forward growth estimate of 11.6%. Priced at its historical normal P/E of 9.7 on the same blended earnings, the 2026-11-06 close of $67.30 corresponds to about $51.20 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Royalty Pharma changed?
tickerseer's rating changed 4 times after 2026-07-31 and is back where it started: trading above its usual valuation as of 2026-11-02.
What is the analyst price target for Royalty Pharma?
The mean Wall Street price target for Royalty Pharma is $65.38 across 8 analysts, 2.9% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.